Skip to main content

Articles

Page 3 of 7

  1. Expression of SRY [sex-determining region Y]-box11 (SOX11) is specific to mantle cell lymphoma (MCL) and contributes, in conjunction with immunoglobulin variable heavy chain gene mutation status, to the identi...

    Authors: Julien Magne, Alizée Jenvrin, Adrien Chauchet, Olivier Casasnovas, Anne Donzel, Laurence Jego, Bernard Aral, Julien Guy, Nathalie Nadal, Dewi Vernerey, Patrick Callier, Francine Garnache-Ottou and Christophe Ferrand

    Citation: Experimental Hematology & Oncology 2018 7:5

    Content type: Rapid communication

    Published on:

  2. Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in pat...

    Authors: Saad Z. Usmani, Imran Khan, Christopher Chiu, David Foureau, Lawrence J. Druhan, Katherine Rigby, Tineke Casneuf and A. Kate Sasser

    Citation: Experimental Hematology & Oncology 2018 7:3

    Content type: Case report

    Published on:

  3. Currently, there are no data available on the best choice of treatment in heavily pretreated patients with advanced breast cancer. However, the combination of oral vinorelbine and capecitabine has been demonst...

    Authors: V. Sgroi, M. Bassanelli, M. Roberto, E. Iannicelli, R. Porrini, P. Pellegrini, A. Tafuri and P. Marchetti

    Citation: Experimental Hematology & Oncology 2018 7:2

    Content type: Case report

    Published on:

  4. The optimal strategy for vaccination to induce CD8+ T cell responses against WT1 is not known.

    Authors: Hongtao Liu, Yuanyuan Zha, Noura Choudhury, Gregory Malnassy, Noreen Fulton, Margaret Green, Jae-Hyun Park, Yusuke Nakamura, Richard A. Larson, Andres M. Salazar, Olatoyosi Odenike, Thomas F. Gajewski and Wendy Stock

    Citation: Experimental Hematology & Oncology 2018 7:1

    Content type: Research

    Published on:

  5. Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreact...

    Authors: Mauricio Sarmiento Maldonado, Pablo Ramírez Villanueva, Pablo Bertín Cortes-Monroy, Veronica Jara Arias, Katherine Soto Donoso, Pablo Uribe Gonzalez, Mauricio Ocqueteau Tachini and Jose Antonio Perez-Simón

    Citation: Experimental Hematology & Oncology 2017 6:32

    Content type: Case report

    Published on:

  6. HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HE...

    Authors: Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li and Kongming Wu

    Citation: Experimental Hematology & Oncology 2017 6:31

    Content type: Review

    Published on:

  7. Pegylated interferon alfa-2a (PEG-IFN-α-2a) is a potent immunomodulating agent capable of inducing high rate of hematologic and even complete molecular remission in patients with essential thrombocythemia (ET)...

    Authors: Lucia Masarova, C. Cameron Yin, Jorge E. Cortes, Marina Konopleva, Gautam Borthakur, Kate J. Newberry, Hagop M. Kantarjian, Carlos E. Bueso-Ramos and Srdan Verstovsek

    Citation: Experimental Hematology & Oncology 2017 6:30

    Content type: Research

    Published on:

  8. The treatment algorithm for metastatic non-small cell lung cancers (NSCLCs) has been evolving rapidly due to the development of new therapeutic agents. Although guidelines are provided by National Comprehensiv...

    Authors: Shuyu D. Li, Annia Martial, Alexa B. Schrock and Jane J. Liu

    Citation: Experimental Hematology & Oncology 2017 6:29

    Content type: Case report

    Published on:

  9. Carfilzomib is approved in the United States and Europe for treatment of relapsed or refractory multiple myeloma (MM). This study evaluated pharmacokinetics (PK) and safety of carfilzomib in patients with rela...

    Authors: Jennifer Brown, Ruth Plummer, Todd M. Bauer, Stephen Anthony, John Sarantopoulos, Filip De Vos, Mike White, Marco Schupp, Ying Ou and Ulka Vaishampayan

    Citation: Experimental Hematology & Oncology 2017 6:27

    Content type: Research

    Published on:

  10. Post-transplant lymphoproliferative disorder is a well-recognized but rare complication of hematopoietic stem cell and solid organ transplant. Due to rarity of this disease, retrospective studies from major tr...

    Authors: Rohit Bishnoi, Ravneet Bajwa, Aaron J. Franke, William Paul Skelton IV, Yu Wang, Niraj M. Patel, William Birdsall Slayton, Fei Zou and Nam H. Dang

    Citation: Experimental Hematology & Oncology 2017 6:26

    Content type: Research

    Published on:

  11. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been considered as a valuable approach in treatment of numerous malignant and none malignant hematologic disorders. However, relapse and poor ...

    Authors: Saeed Mohammadi, Amir Hossein Norooznezhad, Ashraf Malek Mohammadi, Hajar Nasiri, Mohsen Nikbakht, Najmaldin Saki, Mohammad Vaezi, Kamran Alimoghaddam and Ardeshir Ghavamzadeh

    Citation: Experimental Hematology & Oncology 2017 6:24

    Content type: Review

    Published on:

  12. Traditional two-dimensional (2-D) monolayer cell culture is vastly different from in vivo physiological conditions, which can lead to inaccurate or insufficient data in areas where response and efficacy within...

    Authors: Jiaojiao Zhou, Jimmy Su, Xiaotong Fu, Lei Zheng and Zhizhong Yin

    Citation: Experimental Hematology & Oncology 2017 6:22

    Content type: Short report

    Published on:

  13. Heparin-induced thrombocytopenia (HIT) is a life and limb-threatening condition caused by the binding of platelet-activating antibodies (IgG) to multimolecular platelet factor 4 (PF4)/heparin complexes because...

    Authors: Daniel E. Ezekwudo, Rebecca Chacko, Bolanle Gbadamosi, Syeda Batool, Sussana Gaikazian, Theodore E. Warkentin, Jo-Ann I. Sheppard and Ishmael Jaiyesimi

    Citation: Experimental Hematology & Oncology 2017 6:21

    Content type: Case report

    Published on:

  14. B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies. Despite significant improvement on pa...

    Authors: Li Zhang, Yu-Tzu Tai, Matthew Zhi Guang Ho, Lugui Qiu and Kenneth C. Anderson

    Citation: Experimental Hematology & Oncology 2017 6:20

    Content type: Review

    Published on:

  15. Inflammation is a major feature of sickle cell disease (SCD). Low-dose methotrexate (MTX) has long been used in chronic inflammatory diseases. This pilot study examined the MTX effect on acute vaso-occlusive p...

    Authors: Silvia R. Brandalise, Rosemary Assis, Angelo B. A. Laranjeira, José Andrés Yunes and Pedro O. de Campos-Lima

    Citation: Experimental Hematology & Oncology 2017 6:18

    Content type: Research

    Published on:

  16. Cullin 4B (CUL4B) is a scaffold of the Cullin4B-Ring E3 ligase complex (CRL4B) that plays an important role in proteolysis and is implicated in tumorigenesis. Aberrant expression of CUL4B has been reported in ...

    Authors: Ying Li and Xin Wang

    Citation: Experimental Hematology & Oncology 2017 6:17

    Content type: Review

    Published on:

  17. Multiple myeloma (MM) is a type of hematological malignancy with significant heterogeneity in clinical features and prognosis. Cytogenetic abnormalities are the major factors affecting patient outcomes. Studie...

    Authors: GuoQing Wei, LiJun Wang, HanJin Yang, XiaoYan Han, GaoFeng Zheng, WeiYan Zheng, Jie Sun, JiMin Shi, WenJun Wu, Yi Zhao, DongHua He, Bo Wang, Zhen Cai and JingSong He

    Citation: Experimental Hematology & Oncology 2017 6:16

    Content type: Research

    Published on:

  18. Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We evaluat...

    Authors: Virginie Nägele, Andrea Kratzer, Gerhard Zugmaier, Chris Holland, Youssef Hijazi, Max S. Topp, Nicola Gökbuget, Patrick A. Baeuerle, Peter Kufer, Andreas Wolf and Matthias Klinger

    Citation: Experimental Hematology & Oncology 2017 6:14

    Content type: Research

    Published on:

  19. Esophageal cancer including squamous cell carcinoma (SCC) and adenocarcinoma represents 4% of all cancers in the United States. Patients with esophageal cancer frequently present with locally advanced disease,...

    Authors: Natasha Garg, Constance Stoehr, Yan Shi Zhao, Heather Rojas and Chung-Tsen Hsueh

    Citation: Experimental Hematology & Oncology 2017 6:11

    Content type: Case report

    Published on:

  20. Refractory/relapsed B-cell acute lymphoblastic leukemia remains to be a significant cause of cancer-associated morbidity and mortality for children and adults. Developing novel and effective molecular-targeted...

    Authors: Guoqing Wei, Lijuan Ding, Jiasheng Wang, Yongxian Hu and He Huang

    Citation: Experimental Hematology & Oncology 2017 6:10

    Content type: Review

    Published on:

  21. Osteolytic bone lesions and hypercalcemia without peripheral blasts B-cell acute lymphoblastic leukemia (B-ALL) is reported in children but rarely seen in adults.

    Authors: Nikki Charlotta Paul Granacher, Zwi N. Berneman, Wilfried Schroyens, Ann L. R. Van de Velde, Anke Verlinden and Alain P. A. Gadisseur

    Citation: Experimental Hematology & Oncology 2017 6:9

    Content type: Case report

    Published on:

  22. The BRAF K601E mutation occurs in 5% of patients with melanoma, and is the third most common type of BRAF mutation. However, treatment with BRAF and mitogen-activated extracellular signal-regulated kinase (MEK...

    Authors: Riccardo Marconcini, Luca Galli, Andrea Antonuzzo, Simona Bursi, Claudia Roncella, Gabriella Fontanini, Elisa Sensi and Alfredo Falcone

    Citation: Experimental Hematology & Oncology 2017 6:6

    Content type: Case report

    Published on:

  23. Chemotherapy-induced polyneuropathy (CIPN) is a common toxicity after chemotherapy, immunomodulatory drugs or proteasome inhibitors, which is difficult to treat and may also have impact on quality of life. The...

    Authors: Stefan S. Schönsteiner, Heidi Bauder Mißbach, Axel Benner, Silja Mack, Thomas Hamel, Michael Orth, Bernhard Landwehrmeyer, Sigurd D. Süßmuth, Carolin Geitner, Regine Mayer-Steinacker, Anneliese Riester, Andrea Prokein, Elfriede Erhardt, Jelena Kunecki, Anna M. Eisenschink, Rainer Rawer…

    Citation: Experimental Hematology & Oncology 2017 6:5

    Content type: Research

    Published on:

  24. Atypical hemolytic uremic syndrome is a rare disorder which is known to cause acute thrombotic microangiopathy during pregnancy with poor maternal and fetal outcomes. Atypical hemolytic uremic syndrome is cau...

    Authors: Gabriela Andries, Michael Karass, Srikanth Yandrapalli, Katherine Linder, Delong Liu, John Nelson, Rahul Pawar and Savneek Chugh

    Citation: Experimental Hematology & Oncology 2017 6:4

    Content type: Case report

    Published on:

  25. The concept of precision medicine in cancer includes individual molecular studies to predict clinical outcomes. In the present N = 1 case we retrospectively have analysed lymphoma tissue by exome sequencing an...

    Authors: Julie Støve Bødker, Marianne Tang Severinsen, Tarec Christoffer El-Galaly, Rasmus Froberg Brøndum, Maria Bach Laursen, Steffen Falgreen, Mette Nyegaard, Alexander Schmitz, Lasse Hjort Jakobsen, Anna Amanda Schönherz, Hanne Due, Linn Reinholdt, Martin Bøgsted, Karen Dybkær and Hans Erik Johnsen

    Citation: Experimental Hematology & Oncology 2017 6:3

    Content type: Case report

    Published on:

  26. Leukemic and mesenchymal stem cells interact in the leukemic microenvironment and affect each other differently. This interplay has also important implications for the hematopoietic stem cell (HSC) biology and...

    Authors: Natalia-Del Pilar Vanegas and Jean-Paul Vernot

    Citation: Experimental Hematology & Oncology 2017 6:2

    Content type: Research

    Published on:

  27. Targeting BRAF V600E mutation has been proven effective in the treatment of several types of cancer. In endometrial adenocarcinoma, the BRAF V600E mutation has been rarely reported. Whether targeting BRAF onco...

    Authors: Michele Moschetta, Gabriel Mak, Joana Hauser, Catriona Davies, Mario Uccello and Hendrik-Tobias Arkenau

    Citation: Experimental Hematology & Oncology 2017 6:1

    Content type: Case report

    Published on:

  28. Receptor tyrosine kinase, c-Kit (CD117) plays a pivotal role in the maintenance and expansion of hematopoietic stem/progenitor cells (HSPCs). Additionally, over-expression and/or mutational activation of c-Kit...

    Authors: Ningfei An, Bo Cen, Houjian Cai, Jin H. Song, Andrew Kraft and Yubin Kang

    Citation: Experimental Hematology & Oncology 2016 5:31

    Content type: Short report

    Published on:

  29. Breast cancer is the most frequent cause of cancer of women in much of the world. In countries with screening programs, breast cancer is often detected before clinical symptoms are apparent, but occasionally t...

    Authors: Ibrahim Fanous and Patrick Dillon

    Citation: Experimental Hematology & Oncology 2016 5:29

    Content type: Review

    Published on:

  30. Pegylated-interferon alpha (PegINFα) treatment of patients with polycythemia vera (PV) and essential thrombocythemia (ET) has resulted in long-term clinical response, decreased JAK2 V61...

    Authors: Magdalena Kovacsovics-Bankowski, Todd W. Kelley, Olga Efimova, Soo Jin Kim, Andrew Wilson, Sabina Swierczek and Josef Prchal

    Citation: Experimental Hematology & Oncology 2016 5:28

    Content type: Research

    Published on:

  31. The NAD(P)H: quinone oxidoreductase (NQO1) confers protection against semiquinones and also elicits oxidative stress. The C609T polymorphism of the NQO1 gene, designated NQO1*2, significantly reduces its enzymati...

    Authors: Joseph M. Wu, Ardalan Oraee, Barbara B. Doonan, John T. Pinto and Tze-chen Hsieh

    Citation: Experimental Hematology & Oncology 2016 5:27

    Content type: Research

    Published on:

  32. Acute myeloid leukemia (AML) carrying nucleophosmin 1 (NPM1) mutations (NPMc+) is regarded as a separate entity of myeloid neoplasms due to its distinct biological and clinical features. However, NPMc+ alone disp...

    Authors: Hanna Grauers Wiktorin, Tina Nilsson, Ann Jansson, Lars Palmqvist and Anna Martner

    Citation: Experimental Hematology & Oncology 2016 5:25

    Content type: Rapid communication

    Published on:

  33. The increasing understanding of non-small cell lung cancer (NSCLC) biology over the last two decades has led to the identification of multiple molecular targets. This led to the development of multiple targete...

    Authors: David Berz, Victoria M. Raymond, Jordan H. Garst and Mark G. Erlander

    Citation: Experimental Hematology & Oncology 2016 5:24

    Content type: Case report

    Published on:

  34. With the rapid succession of new effective agents for melanoma in the recent years, the paradigm for treatment of metastatic melanoma is changing. The success of combining multiple effective agents compared wi...

    Authors: Eddy C. Hsueh and Kalyan C. Gorantla

    Citation: Experimental Hematology & Oncology 2016 5:23

    Content type: Review

    Published on:

  35. Blocking mTOR (molecular target of rapamycin) by sirolimus has been shown to suppress cellular respiration. The bearing of this impaired cellular bioenergetics on the mode-of-action of mTOR inhibitors has yet ...

    Authors: Suleiman Al-Hammadi, Saeeda Almarzooqi, Alia Albawardi and Abdul-Kader Souid

    Citation: Experimental Hematology & Oncology 2016 5:22

    Content type: Research

    Published on:

  36. B Acute Lymphoblastic leukemia (B-ALL) with Philadelphia chromosome (Ph′) is a neoplasm of lymphoblast committed to the B cell lineage. The clinical presentation of B-ALL Ph′+ is similar to B-ALL, but is more ...

    Authors: Bernardo López-Andrade, Francesca Sartori, Antonio Gutiérrez, Lucia García, Vanesa Cunill, María Antonia Durán, Antonia Sampol, Marta Bernués, Julio Iglesias, Rafael Ramos, Josep Lladó, María Sánchez, Juan Carlos Amat and Jordi Martínez-Serra

    Citation: Experimental Hematology & Oncology 2016 5:21

    Content type: Case report

    Published on:

  37. The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy.

    Authors: Katherine Linder, Deepthi Gandhiraj, Madhura Hanmantgad, Karen Seiter and Delong Liu

    Citation: Experimental Hematology & Oncology 2016 5:20

    Content type: Case report

    Published on:

  38. AMD3100, also known as plerixafor, was originally developed as an anti-human immunodeficiency virus (HIV) drug, and later characterized as a C-X-C chemokine receptor type 4 (CXCR4) antagonist. Previous reviews...

    Authors: Tao Liu, Xiaobo Li, Shuo You, Soumitra S. Bhuyan and Lei Dong

    Citation: Experimental Hematology & Oncology 2016 5:19

    Content type: Review

    Published on:

Annual Journal Metrics